The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $80.36

Today's change-0.39 -0.48%
Updated May 6 10:49 AM EDT. Delayed by at least 15 minutes.
 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $80.36

Today's change-0.39 -0.48%
Updated May 6 10:49 AM EDT. Delayed by at least 15 minutes.

Charles River Laboratories International Inc down (U.S.)$0.39

Charles River Laboratories International Inc is lower today, dropping (U.S.)$0.39 or 0.48% to (U.S.)$80.36. Over the last five days, shares have gained 1.38%, but are currently unchanged over the last year to date. Shares have outperformed the S&P 500 by 16.21% during the last year.

Key company metrics

  • Open(U.S.) $80.28
  • Previous close(U.S.) $80.75
  • High(U.S.) $81.22
  • Low(U.S.) $79.96
  • Bid / Ask(U.S.) $80.33 / (U.S.) $80.39
  • YTD % change-0.037%
  • Volume75,338
  • Average volume (10-day)488,028
  • Average volume (1-month)503,128
  • Average volume (3-month)593,258
  • 52-week range(U.S.) $59.99 to (U.S.) $82.40
  • Beta1.25
  • Trailing P/E24.51×
  • P/E 1 year forward18.49×
  • Forward PEG1.46×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $3.28
Updated May 6 10:49 AM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+11.30%

Based on its net profit margin of 11.30%, Charles River Laboratories International Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.62%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 26, 201512/26/2015Sep 26, 201509/26/2015Jun 27, 201506/27/2015Mar 28, 201503/28/2015
Revenue354349340320
Total other revenue--------
Total revenue354349340320
Gross profit141138133120
Total cost of revenue213211207201
Total operating expense302294284277
Selling / general / administrative81767171
Research & development--------
Depreciation / amortization7665
Interest expense (income), net operating--------
Unusual expense (income)----11
Other operating expenses, total--------
Operating income52555643
Interest income (expense), net non-operating-4-4-4-3
Gain (loss) on sale of assets--------
Other--------
Income before tax50536032
Income after tax33384932
Income tax, total1715110
Net income32374932
Total adjustments to net income--------
Net income before extra. items33374932
Minority interest00-10
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items33374932
Inc. avail. to common incl. extra. items32374932
Diluted net income32374932
Dilution adjustment0----0
Diluted weighted average shares48474848
Diluted EPS excluding extraordinary itemsvalue per share0.690.791.020.66
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.690.791.030.68